Fully automatic MRI-based hippocampus volumetry using FSL-FIRST: intra-scanner test-retest stability, inter-field strength variability, and performance as enrichment biomarker for clinical trials using prodromal target populations at risk for Alzheimer’s

Manuscript Number: 

16-1108R2

Author(s): 
Ralph Buchert, Enrica Cavedo, Samantha Galluzzi, Harald Hampel, Catharina Lange, Simone Lista, Roland Opfer, Adam J. Schwarz, Lothar Spies, Per Suppa

Disclosures

Ralph Buchert

  • Nothing to Disclose

Enrica Cavedo

  • Nothing to Disclose

Samantha Galluzzi

  • Nothing to Disclose

Harald Hampel

  • Consulting Fees:
    Infrequent scientific consultancy and/or advisory board activities with Eli Lilly and company, GE Healthcare, Roche Diagnostics, Cytox, Jung Diagnostics, Anavex, Axovant, Oryzon Genomics
    Lecture Fees:
    Infrequent or single scientific lectures at scientific meetings supported by Axovant, Biogen, Roche, Cytox, Eli Lilly and company
    Patents/Royalties
    I have patents as co-inventor, but received no royalties.

Catharina Lange

  • Nothing to Disclose

Simone Lista

  • Lecture Fees:
    Simone Lista received lecture honoraria from Roche.

Roland Opfer

  • Nothing to Disclose

Adam J. Schwarz

  • Equity:
    Eli Lilly and Company (minor stockholder)
    Patents/Royalties
    Full time employee of Eli Lilly and Company

Lothar Spies

  • Nothing to Disclose

Per Suppa

  • Nothing to Disclose